Sofinnova Partners Leads Inventiva Pharma €35,5 M Capital Increase• Sofinnova Partners invested €10 M in the capital increase. • Funds will be used to advance the clinical programs of the company’s portfolio compounds. • A representative of Sofinnova Partners shall be designated at the Board of directors of Inventiva. PARIS, April 19, 2018-- Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, announced today it has led Inventiva Pharma (IVA) €35,5 M capital increase through its newly created Sofinnova Crossover I Fund. Sofinnova Partners invested €10 M, becoming one of the company’s largest investors.